A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies.
A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies.
复制标题
DOI：
10.1002/cti2.1195
复制
发表时间：
2020
影响因子：
5.8
通讯作者：
Lu X
中科院分区：
文献类型：
--
作者：
Chen H;Yang H;Cheng QX;Ge YP;Peng QL;Zhang YM;Cheng GH;Wang GC;Lu X
研究特发性炎症性肌病（IIM）患者中抗钙网蛋白自身抗体（anti - CRT Ab）的流行情况及其临床意义。采用人重组CRT蛋白酶联免疫吸附法对469例IIM患者、196例其他结缔组织疾病患者、28例实体瘤患者和81例健康对照者的血清进行抗CRT抗体的筛选。使用免疫沉淀法检测35例IIM患者的血清，以确认抗CRT抗体的存在。随后，IIM癌症患者被识别并根据其癌症状态分为新发、缓解和复发组。我们还研究了抗CRT抗体水平与IIM疾病活动度之间的关系。469例IIM患者中有81例（17.3%）血清抗CRT抗体阳性。在与CRT蛋白对应的60 kDa分子量处观察到免疫沉淀带。与没有抗CRT抗体的患者相比，有抗CRT抗体的IIM患者更容易发生癌症。而且，抗CRT抗体的患病率因癌症状态而异。癌症复发的IIM患者的抗CRT抗体比癌症缓解期患者高得多。此外，血清抗CRT抗体水平与基线和随访时的疾病活动度呈正相关。我们报道了IIM患者血清中抗CRT抗体的存在，并证明了抗CRT抗体与IIM患者恶性肿瘤的可能关联。血清抗CRT抗体可作为IIM患者癌症的一种新的候选标志物。据我们所知，这是第一份描述成人发病特发性炎症性肌病（IIM）患者血清抗钙网蛋白自身抗体（anti - CRT Ab）的患病率和临床意义的报告。血清抗CRT抗体可作为IIM患者癌症的一种新的候选标志物，检测抗CRT抗体可用于监测有实体瘤病史的IIM患者的癌症复发。
To investigate the prevalence and clinical significance of anti‐calreticulin autoantibodies (anti‐CRT Ab) in a large cohort of idiopathic inflammatory myopathy (IIM) patients. Sera from 469 patients with IIM, 196 patients with other connective tissue diseases, 28 patients with solid tumors and 81 healthy controls were screened for anti‐CRT Ab by enzyme‐linked immunosorbent assay using human recombinant CRT protein. Sera from 35 IIM patients were tested using an immunoprecipitation assay to confirm the presence of anti‐CRT Ab. Subsequently, IIM–cancer patients were identified and divided into new‐onset, remission and recurrent groups based on their cancer status. The relationships between anti‐CRT Ab levels and IIM disease activity were also investigated. Serum anti‐CRT Ab was detected positive in 81 of the 469 (17.3%) IIM patients. Immunoprecipitated bands were observed at a molecular weight of 60 kDa corresponding to the CRT protein. The IIM patients with anti‐CRT Ab more frequently had cancers compared to the patients without anti‐CRT Ab. Moreover, the prevalence of anti‐CRT Ab differed according to the cancer status. The IIM patients with recurrent cancers had a much higher prevalence of anti‐CRT Ab than those with cancers in remission. Also, serum anti‐CRT Ab levels positively correlated with disease activity at baseline and at follow‐up visits. We report the existence of serum anti‐CRT Ab in IIM patients and demonstrate the possible association of anti‐CRT Ab with malignancy in IIM patients. Serum anti‐CRT Ab could serve as a novel candidate marker of cancer in IIM patients. To our knowledge, this is the first report to describe the prevalence and clinical significance of serum anti‐calreticulin autoantibodies (anti‐CRT Ab) in a large cohort of adult‐onset idiopathic inflammatory myopathy (IIM) patients. Serum anti‐CRT Ab could serve as a novel candidate marker of cancer in IIM patients, and detection of anti‐CRT Ab could be valuable in monitoring cancer recurrence in IIM patients with a history of solid tumors.
登录
查看更多内容
影响因子：
14.5
作者：
Allenbach, Yves;Keraen, Jeremy;Benveniste, Olivier
通讯作者：
Benveniste, Olivier
影响因子：
5.5
作者：
Isenberg, DA;Allen, E;Miller, F
通讯作者：
Miller, F
影响因子：
27.4
作者：
Lundberg IE;Tjärnlund A;Bottai M;Werth VP;Pilkington C;Visser M;Alfredsson L;Amato AA;Barohn RJ;Liang MH;Singh JA;Aggarwal R;Arnardottir S;Chinoy H;Cooper RG;Dankó K;Dimachkie MM;Feldman BM;Torre IG;Gordon P;Hayashi T;Katz JD;Kohsaka H;Lachenbruch PA;Lang BA;Li Y;Oddis CV;Olesinska M;Reed AM;Rutkowska-Sak L;Sanner H;Selva-O'Callaghan A;Song YW;Vencovsky J;Ytterberg SR;Miller FW;Rider LG;International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland)
通讯作者：
International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland)
影响因子：
3.5
作者：
Eric-Nikolic, Aleksandra;Milovanovic, Zorka;Juranic, Zorica
通讯作者：
Juranic, Zorica
影响因子：
158.5
作者：
BOHAN, A;PETER, JB
通讯作者：
PETER, JB